Cerebrospinal Fluid Biomarkers Measured by Elecsys Assays Compared to Amyloid Imaging

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2018 Mar 5

PMID 29501462

Citations 142

Authors

Suzanne E Schindler

Julia D Gray

Brian A Gordon

Chengjie Xiong

Richard Batrla-Utermann

Marian Quan

Simone Wahl

Tammie L S Benzinger

David M Holtzman

John C Morris

Anne M Fagan

Affiliations

Soon will be listed here.

Abstract

Introduction: Levels of amyloid β peptide 42 (Aβ42), total tau, and phosphorylated tau-181 are well-established cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease, but variability in manual plate-based assays has limited their use. We examined the relationship between CSF biomarkers, as measured by a novel automated immunoassay platform, and amyloid positron emission tomography.

Methods: CSF samples from 200 individuals underwent separate analysis for Aβ42, total tau, and phosphorylated tau-181 with automated Roche Elecsys assays. Aβ40 was measured with a commercial plate-based assay. Positron emission tomography with Pittsburgh Compound B was performed less than 1 year from CSF collection.

Results: Ratios of CSF biomarkers (total tau/Aβ42, phosphorylated tau-181/Aβ42, and Aβ42/Aβ40) best discriminated Pittsburgh Compound B-positive from Pittsburgh Compound B-negative individuals.

Discussion: CSF biomarkers and amyloid positron emission tomography reflect different aspects of Alzheimer's disease brain pathology, and therefore, less-than-perfect correspondence is expected. Automated assays are likely to increase the utility of CSF biomarkers.

Citing Articles

TREM2 risk variants and associated endophenotypes in alzheimer's disease.

Dijkstra J, Vermunt L, Venkatraghavan V, Ozhegov G, Coomans E, Ossenkoppele R Alzheimers Res Ther. 2025; 17(1):57.

PMID: 40051009 PMC: 11883996. DOI: 10.1186/s13195-025-01700-2.

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.

Leuzy A, Bollack A, Pellegrino D, Teunissen C, La Joie R, Rabinovici G Alzheimers Dement. 2025; 21(3):e14528.

PMID: 40042435 PMC: 11881640. DOI: 10.1002/alz.14528.

Association of CSF soluble TREM1 levels with hippocampal atrophy in cognitively impaired older adults.

Shu H, Ding G, Xu X, Huang X, He R Front Aging Neurosci. 2025; 16:1481526.

PMID: 39877076 PMC: 11772463. DOI: 10.3389/fnagi.2024.1481526.

Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice.

Jack C, Graf A, Burnham S, Doty E, Moebius H, Montenigro P Alzheimers Dement (N Y). 2025; 10(4):e70013.

PMID: 39748835 PMC: 11694534. DOI: 10.1002/trc2.70013.

The CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease.

Cacciaglia R, Shekari M, Salvado G, Mila-Aloma M, Falcon C, Sanchez-Benavides G Brain Commun. 2024; 7(1):fcae451.

PMID: 39723106 PMC: 11668178. DOI: 10.1093/braincomms/fcae451.

References

Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein M, Bowser R . Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42. Biomark Med. 2012; 6(4):409-17. DOI: 10.2217/bmm.12.39. View

Vos S, Visser P, Verhey F, Aalten P, Knol D, Ramakers I . Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice. PLoS One. 2014; 9(6):e100784. PMC: 4069102. DOI: 10.1371/journal.pone.0100784. View

Fagan A, Shaw L, Xiong C, Vanderstichele H, Mintun M, Trojanowski J . Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol. 2011; 68(9):1137-44. PMC: 3154969. DOI: 10.1001/archneurol.2011.105. View

Fagan A, Roe C, Xiong C, Mintun M, Morris J, Holtzman D . Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007; 64(3):343-9. DOI: 10.1001/archneur.64.3.noc60123. View

Lewczuk P, Matzen A, Blennow K, Parnetti L, Molinuevo J, Eusebi P . Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease. J Alzheimers Dis. 2016; 55(2):813-822. PMC: 5147502. DOI: 10.3233/JAD-160722. View

Palmqvist S, Mattsson N, Hansson O . Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain. 2016; 139(Pt 4):1226-36. PMC: 4806222. DOI: 10.1093/brain/aww015. View

Su Y, Blazey T, Snyder A, Raichle M, Marcus D, Ances B . Partial volume correction in quantitative amyloid imaging. Neuroimage. 2014; 107:55-64. PMC: 4300252. DOI: 10.1016/j.neuroimage.2014.11.058. View

Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K . Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol. 2010; 95(4):579-93. DOI: 10.1016/j.pneurobio.2010.11.005. View

Shaw L, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K . Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011; 121(5):597-609. PMC: 3175107. DOI: 10.1007/s00401-011-0808-0. View

10.

Mintun M, Larossa G, Sheline Y, Dence C, Lee S, Mach R . [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006; 67(3):446-52. DOI: 10.1212/01.wnl.0000228230.26044.a4. View

11.

Wang J, Tan L, Yu J . Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives. J Alzheimers Dis. 2016; 50(4):927-45. DOI: 10.3233/JAD-150826. View

12.

Li G, Sokal I, Quinn J, Leverenz J, Brodey M, Schellenberg G . CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007; 69(7):631-9. DOI: 10.1212/01.wnl.0000267428.62582.aa. View

13.

Morris J, Selkoe D . Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview. Neurobiol Aging. 2011; 32 Suppl 1:S1-3. DOI: 10.1016/j.neurobiolaging.2011.09.005. View

14.

Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R . Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging. 2007; 30(5):682-90. PMC: 2774781. DOI: 10.1016/j.neurobiolaging.2007.08.010. View

15.

Galasko D, Chang L, Motter R, Clark C, Kaye J, Knopman D . High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998; 55(7):937-45. DOI: 10.1001/archneur.55.7.937. View

16.

Price J, McKeel Jr D, Buckles V, Roe C, Xiong C, Grundman M . Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009; 30(7):1026-36. PMC: 2737680. DOI: 10.1016/j.neurobiolaging.2009.04.002. View

17.

Fagan A, Mintun M, Mach R, Lee S, Dence C, Shah A . Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2005; 59(3):512-9. DOI: 10.1002/ana.20730. View

18.

Beach T, Monsell S, Phillips L, Kukull W . Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012; 71(4):266-73. PMC: 3331862. DOI: 10.1097/NEN.0b013e31824b211b. View

19.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228-34. DOI: 10.1016/S1474-4422(06)70355-6. View

20.

Frisoni G, Bocchetta M, Chetelat G, Rabinovici G, de Leon M, Kaye J . Imaging markers for Alzheimer disease: which vs how. Neurology. 2013; 81(5):487-500. PMC: 3776529. DOI: 10.1212/WNL.0b013e31829d86e8. View